Elektrofi

Elektrofi company information, Employees & Contact Information

Explore related pages

Related company profiles:

Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, Hypercon™, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are headquartered in Boston and innovate globally. Formulating the Future of Biologics™. www.Elektrofi.com

Company Details

Employees
98
Founded
-
Address
25 Drydock Ave, Floor 2,united States
Email
in****@****ofi.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Boston, Massachusetts
Looking for a particular Elektrofi employee's phone or email?

Elektrofi Questions

News

Halozyme’s $900M Elektrofi Buyout Brings Two Big Pharma Partners Together - BioSpace

Halozyme’s $900M Elektrofi Buyout Brings Two Big Pharma Partners Together BioSpace

Halozyme buys subcutaneous drug delivery peer Elektrofi for up to $900M - Fierce Pharma

Halozyme buys subcutaneous drug delivery peer Elektrofi for up to $900M Fierce Pharma

Halozyme eyes microparticles in $900m Elektrofi acquisition - Pharmaceutical Technology

Halozyme eyes microparticles in $900m Elektrofi acquisition Pharmaceutical Technology

Halozyme to buy Elektrofi in up to $900 million deal to expand drug delivery lineup - Reuters

Halozyme to buy Elektrofi in up to $900 million deal to expand drug delivery lineup Reuters

Elektrofi Announces Oversubscribed $112.25 Million Series C Financing to Establish Commercial-Scale GMP Manufacturing Capacity & Accelerate Clinical Development Across its Growing Portfolio of Partnered Programs - PR Newswire

Elektrofi Announces Oversubscribed $112.25 Million Series C Financing to Establish Commercial-Scale GMP Manufacturing Capacity & Accelerate Clinical Development Across its Growing Portfolio of Partnered Programs PR Newswire

Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth? - Yahoo Finance

Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth? Yahoo Finance

Halozyme Enters $750 Million Definitive Agreement with Elektrofi Aiming to Expand Drug Delivery and Bolster Long-Term Growth - Pharmaceutical Executive

Halozyme Enters $750 Million Definitive Agreement with Elektrofi Aiming to Expand Drug Delivery and Bolster Long-Term Growth Pharmaceutical Executive

Halozyme Therapeutics to Acquire Elektrofi - Contract Pharma

Halozyme Therapeutics to Acquire Elektrofi Contract Pharma

Halozyme to spend $750M upfront to buy Elektrofi, a biologics tech delivery company - Endpoints News

Halozyme to spend $750M upfront to buy Elektrofi, a biologics tech delivery company Endpoints News

Protein Microparticles Turn Infusions into Injectables - Genetic Engineering and Biotechnology News

Protein Microparticles Turn Infusions into Injectables Genetic Engineering and Biotechnology News

California company swoops in with $750M to buy Boston biotech - The Business Journals

California company swoops in with $750M to buy Boston biotech The Business Journals

Halozyme To Acquire Elektrofi; Reaffirms 2025 Guidance Ranges - Nasdaq

Halozyme To Acquire Elektrofi; Reaffirms 2025 Guidance Ranges Nasdaq

Elektrofi Raises $40 Million Financing to Establish GMP Manufacturing Capabilities for Upcoming Clinical Studies and Expand Development Pipeline - Business Wire

Elektrofi Raises $40 Million Financing to Establish GMP Manufacturing Capabilities for Upcoming Clinical Studies and Expand Development Pipeline Business Wire

Elektrofi bags $40m funding to establish manufacturing line - BioProcess International

Elektrofi bags $40m funding to establish manufacturing line BioProcess International

Halozyme Announces Merger Agreement with Elektrofi - TipRanks

Halozyme Announces Merger Agreement with Elektrofi TipRanks

Elektrofi, Janssen Biotech form collaboration - The Cancer Letter

Elektrofi, Janssen Biotech form collaboration The Cancer Letter

Halozyme Sparks With Elektrofi Acquisition, Expanding Partnering Options - Citeline News & Insights

Halozyme Sparks With Elektrofi Acquisition, Expanding Partnering Options Citeline News & Insights

$750M Drug Delivery Tech Deal: Halozyme Acquires Elektrofi's Revolutionary 500mg/ml Biologics Platform - Stock Titan

$750M Drug Delivery Tech Deal: Halozyme Acquires Elektrofi's Revolutionary 500mg/ml Biologics Platform Stock Titan

Elektrofi Enters Global Collaboration and License Agreement with argenx to Explore New Subcutaneous Product Formulations - Business Wire

Elektrofi Enters Global Collaboration and License Agreement with argenx to Explore New Subcutaneous Product Formulations Business Wire

Eli Lilly gives $20M upfront cash injection to Elektrofi in next-gen subcutaneous drug collab - Fierce Biotech

Eli Lilly gives $20M upfront cash injection to Elektrofi in next-gen subcutaneous drug collab Fierce Biotech

Biologics delivery startup Elektrofi bags $40M for clinical push - Fierce Pharma

Biologics delivery startup Elektrofi bags $40M for clinical push Fierce Pharma

Halozyme's $900M Hypercon Bet: Will Elektrofi Redefine SubQ Drug Delivery? - Smartkarma

Halozyme's $900M Hypercon Bet: Will Elektrofi Redefine SubQ Drug Delivery? Smartkarma

Exclusive: Boston biotech Elektrofi seals $470M-plus deal with Eli Lilly - The Business Journals

Exclusive: Boston biotech Elektrofi seals $470M-plus deal with Eli Lilly The Business Journals

Argenx taps Elektrofi to develop subcutaneous anti-FcRn drugs - Fierce Pharma

Argenx taps Elektrofi to develop subcutaneous anti-FcRn drugs Fierce Pharma

Elektrofi, Argenx enter collaboration for subcutaneous product formulations - Drug Delivery Business

Elektrofi, Argenx enter collaboration for subcutaneous product formulations Drug Delivery Business

Top Elektrofi Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant